| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC1931 |
| Trial ID | NCT03598179 |
| Disease | B-Cell Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | XLCAR-T001 |
| Phase | Phase2 |
| Recruitment status | Unknown |
| Title | XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects |
| Year | 2018 |
| Country | China |
| Company sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Other ID(s) | JSPH-CART001 |
| Vector information | |||
|
|||
| Cohort1: dose level 1 | |||||||
|
|||||||
| Cohort2: dose level 2 | |||||||
|
|||||||
| Cohort3: dose level 3 | |||||||
|
|||||||